Structure Therapeutics is trading 4.4% up at $49.45 as part of a broader risk-on move across the biotech sector and major U.S. indices.
- The stock is climbing in tandem with strength in the wider market, with no fresh company-specific catalysts reported.
- Pre-market commentary suggests today's gains are primarily driven by sector and macro sentiment rather than new developments from the company.